Dialysis Market Size, Share & Trends Analysis Report By Product (Hemodialysis, Peritoneal Dialysis), By Applications (In-center Dialysis, Home Dialysis), By End Use, By Region, and Segment Forecasts - 2035

Dialysis Market Overview

The dialysis market was valued at USD 122875.75 million in 2025, The market is set to reach USD 130346.6 million by 2026-end and grow at a CAGR of 6.08% between 2026-2035 to reach USD 221739.02 million by 2035.

The dialysis market continues to expand as chronic kidney disease, diabetes, hypertension, population aging, and improved diagnosis increase the number of patients requiring long-term renal replacement therapy. More than 4 million people worldwide currently depend on dialysis, while kidney disorders affect more than 850 million individuals globally. Hemodialysis remains the most widely utilized treatment method and represents approximately 88% of dialysis procedures, supported by extensive hospital and outpatient treatment infrastructure. Peritoneal dialysis accounts for about 12% and is increasingly adopted as healthcare systems encourage treatment outside conventional dialysis centers. A standard in-center hemodialysis patient generally receives 3 treatment sessions per week, with individual sessions commonly lasting approximately 4 hours. Meanwhile, connected dialysis machines, remote patient management, automated treatment systems, portable equipment, and high-volume hemodiafiltration are strengthening the technological profile of the industry. Home treatment is particularly important to future market development because it can improve scheduling flexibility while reducing repeated travel to dialysis facilities.

The United States remains one of the most developed dialysis markets, supported by a large kidney-failure population, extensive reimbursement coverage, and more than 7,500 dialysis facilities operating nationwide. More than 550,000 patients receive dialysis in the country, while approximately 15% of dialysis patients were receiving treatment in a home setting during 2025. Home hemodialysis adoption is strengthening, with more than 15,300 U.S. patients using NxStage systems during 2025, representing approximately 6% growth compared with the previous year. Technology adoption is also advancing through hemodiafiltration-capable platforms, digital interfaces, remote treatment monitoring, and patient-guidance software. The commercialization of newer hemodiafiltration systems during 2026 is expected to broaden treatment options across U.S. dialysis facilities, while connected home-dialysis platforms are increasing coordination between patients and clinical teams. These developments indicate that the U.S. market is gradually shifting from a predominantly facility-centered model toward a more diversified combination of in-center and home-based renal care.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Hemodialysis is expected to retain the leading position through the forecast period, accounting for approximately 88% of dialysis procedures as extensive clinical infrastructure and established treatment protocols support its widespread utilization.
• Leading Application: In-center Dialysis remains the dominant application, representing approximately 85% of current treatment activity, supported by continuous clinical supervision, established dialysis facilities, specialized nursing teams, and accessibility for medically complex patients.
• Leading Region: North America is expected to maintain market leadership with approximately 38% participation, supported by extensive treatment infrastructure, high kidney-failure prevalence, strong reimbursement mechanisms, and rapid adoption of advanced dialysis technologies.
• Fastest Growing Region: Asia-Pacific is projected to record the strongest expansion, with approximately 25% current market participation and more than 2 million patients receiving dialysis as treatment availability improves across major developing economies.
• Technology Trend: Connected home dialysis is becoming an important technology direction, with more than 15,300 U.S. patients using NxStage home hemodialysis systems in 2025 alongside growing adoption of remote monitoring and guided treatment platforms.
• Market Driver: Rising chronic kidney disease prevalence remains the principal demand catalyst, with kidney disorders affecting more than 850 million people globally and diabetes and hypertension continuing to contribute substantially to progression toward kidney failure.
• Competitive Landscape: Leading manufacturers are accelerating technology commercialization, while more than 100,000 dialysis machines support treatment infrastructure worldwide and newer systems increasingly emphasize connectivity, treatment guidance, portability, automation, and higher-efficiency dialysis procedures.
• Future Outlook: Home-based kidney care will gain greater strategic importance through 2035 as current home dialysis penetration remains near 15% in the United States, leaving substantial scope for increased patient training, connectivity, and decentralized treatment.

Latest Trends

Home dialysis is emerging as one of the most influential trends reshaping the dialysis market as healthcare providers seek to provide greater patient flexibility while relieving capacity pressure on conventional treatment facilities. Around 15% of U.S. dialysis patients were treated at home during 2025, and the number of patients using NxStage home hemodialysis systems in the country surpassed 15,300, increasing approximately 6% from more than 14,500 during the preceding year. Home hemodialysis equipment is becoming more user-oriented through touchscreen interfaces, graphical treatment guidance, automated workflows, simplified setup procedures, and remote connectivity. Peritoneal Dialysis is also benefiting from connected cyclers and remote patient management, enabling clinical teams to review treatment information without requiring every interaction to occur inside a dialysis center. During 2026, unified digital platforms capable of supporting both Peritoneal Dialysis and home Hemodialysis are further strengthening connected kidney-care models. These advancements are gradually changing dialysis from a treatment defined primarily by fixed clinical locations into a more flexible therapy ecosystem involving patient homes, outpatient facilities, clinical monitoring systems, and digitally connected healthcare professionals.

Another major trend is the adoption of higher-performance dialysis technologies intended to improve clearance efficiency, treatment personalization, reliability, and clinical monitoring. High-volume hemodiafiltration is receiving increased attention in the United States following regulatory progress for newer hemodiafiltration-capable systems, with broader commercialization activity extending into 2026. Modern dialysis platforms increasingly combine automated controls, treatment-data recording, touchscreen navigation, cybersecurity protection, predictive alerts, and real-time monitoring to improve usability for both healthcare professionals and patients. At the same time, dialysis providers are strengthening digital infrastructure because approximately 3 treatment sessions per week remain standard for many conventional Hemodialysis patients, generating substantial volumes of recurring clinical data. Remote platforms can help clinicians identify treatment deviations, review adherence, and manage multiple home patients without relying entirely on physical appointments. Equipment developers are therefore prioritizing interoperability between machines, software, patient-management systems, and clinical workflows, making digital integration an increasingly important competitive differentiator throughout the 2026-2035 forecast period.

Market Dynamics

Driver

""Rising kidney disease burden is sustaining long-term dialysis demand.""

Increasing prevalence of chronic kidney disease and end-stage kidney failure remains the strongest structural driver of the dialysis market. Kidney disorders affect more than 850 million people worldwide, while millions of patients eventually require renal replacement therapy when kidney function declines beyond manageable levels. More than 4 million people currently receive dialysis globally, creating recurring demand for treatment sessions, machines, dialyzers, tubing, concentrates, monitoring equipment, and associated clinical services. Diabetes and hypertension remain among the most important underlying causes of kidney failure, and their increasing prevalence expands the population at risk of requiring dialysis. Population aging further strengthens demand because kidney function commonly declines with age and older patients frequently present with several chronic conditions simultaneously. Hemodialysis consequently retains approximately 88% of treatment activity, supported by established clinical protocols and extensive facility infrastructure. With conventional treatment often performed 3 times each week and lasting about 4 hours per session, every additional long-term patient creates substantial recurring capacity requirements, encouraging healthcare systems and providers to increase dialysis infrastructure and introduce more efficient treatment technologies.

Restraint

""Treatment intensity and clinical complications restrict wider therapy flexibility.""

The substantial treatment burden associated with dialysis remains an important restraint despite continuous improvements in machines and clinical procedures. Conventional in-center Hemodialysis frequently requires patients to attend approximately 3 sessions every week, with each treatment commonly extending for around 4 hours before transportation and recovery time are considered. This schedule can interfere with employment, education, family responsibilities, and travel, particularly for patients requiring therapy continuously for several years. Vascular-access complications, infection risks, intradialytic hypotension, fatigue, fluid-management difficulties, and cardiovascular stress can additionally increase the clinical burden associated with long-term treatment. Home Dialysis can reduce some logistical limitations, but adoption remains around 15% of dialysis patients in the United States, illustrating continuing barriers involving patient eligibility, training requirements, housing conditions, caregiver support, equipment confidence, and clinical oversight. Home Hemodialysis may also require more frequent vascular-access use depending on the prescription, while Peritoneal Dialysis requires rigorous infection-control practices. These factors prevent rapid migration away from established In-center Dialysis even as healthcare systems seek more flexible treatment models.

Opportunity

""Connected home treatment creates substantial scope for decentralized renal care.""

Expansion of Home Dialysis represents one of the clearest growth opportunities for dialysis providers and equipment manufacturers during the 2026-2035 period. With approximately 15% of U.S. dialysis patients currently receiving treatment at home, the majority of the patient population remains dependent on facility-based care, leaving considerable room for appropriate patients to transition toward home-based therapy. More than 15,300 U.S. patients used NxStage home Hemodialysis systems during 2025, increasing about 6% compared with 2024 and demonstrating measurable momentum in patient adoption. Digital platforms introduced during 2026 are extending this opportunity by combining remote therapy information, clinical workflows, Peritoneal Dialysis management, and home Hemodialysis monitoring within connected environments. Improved touchscreen interfaces, graphical treatment guidance, automated data transfer, remote support, and compact machine designs can lower practical barriers associated with patient training and equipment operation. Healthcare systems can also benefit because increased home treatment may relieve demand on physical dialysis stations, allowing existing facilities to allocate capacity toward patients requiring more intensive clinical supervision.

Challenge

""Workforce capacity and infrastructure requirements complicate treatment expansion.""

Scaling dialysis access while maintaining consistent treatment quality remains a major operational challenge as the global patient population exceeds 4 million. In-center Dialysis requires specialized nurses, nephrologists, technicians, water-treatment infrastructure, dialysis stations, infection-control systems, equipment maintenance, and continuous supplies of treatment consumables. A single conventional Hemodialysis patient receiving approximately 3 sessions weekly can require more than 150 treatment visits during one year, demonstrating how quickly rising patient numbers translate into staffing and infrastructure pressure. Home Dialysis can distribute treatment capacity beyond clinical facilities, but it introduces different requirements involving patient education, equipment installation, remote monitoring, technical support, supply delivery, emergency procedures, and caregiver readiness. The market must therefore expand both clinical and digital capabilities rather than relying exclusively on additional treatment centers. Maintaining cybersecurity is also becoming more important as newer machines and remote platforms exchange treatment information electronically. Manufacturers and providers must balance connectivity, usability, reliability, patient safety, and clinical oversight while supporting an expanding kidney-failure population throughout the forecast period.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The dialysis market is segmented by type into Hemodialysis and Peritoneal Dialysis and by application into In-center Dialysis and Home Dialysis. Hemodialysis continues to account for the majority of treatments worldwide, while Home Dialysis is gaining importance as connected platforms, compact equipment, remote patient monitoring, and patient-friendly systems improve treatment flexibility. Approximately 450 million hemodialysis dialyzers were used globally during 2025, compared with about 430 million in 2024, while an estimated 110,000 hemodialysis machines were installed during 2025. The continuing expansion of treatment capacity, combined with greater emphasis on home-based therapy, is creating distinct growth patterns across both type and application segments.

By Types

Hemodialysis: Hemodialysis accounts for approximately 88% of the dialysis treatment mix and remains the leading product type because of its established clinical infrastructure, broad physician acceptance, standardized treatment protocols, and suitability for patients requiring intensive medical supervision. The global hemodialysis ecosystem consumed approximately 450 million dialyzers during 2025, increasing from about 430 million units in 2024. Around 110,000 hemodialysis machines were installed globally during 2025, compared with approximately 100,000 during the preceding year, demonstrating continuing infrastructure expansion. A conventional patient typically undergoes about 3 sessions each week, producing more than 150 treatment sessions annually for long-term patients. In-center facilities remain the principal environment for Hemodialysis, although home systems are gaining adoption because compact equipment and remote monitoring reduce dependence on fixed clinical locations. High-volume hemodiafiltration-capable systems are further strengthening this segment by extending treatment beyond conventional diffusion-based Hemodialysis. Fresenius Medical Care held more than 40% of the global hemodialysis products market during 2025, highlighting substantial competitive concentration in machines, dialyzers, and associated treatment technologies.

Peritoneal Dialysis: Peritoneal Dialysis represents approximately 12% of the global dialysis treatment mix and is gaining strategic importance because it allows patients to perform therapy outside conventional dialysis centers. The treatment is particularly aligned with Home Dialysis because automated peritoneal dialysis systems can operate overnight while connected platforms transmit completed treatment information to healthcare teams. Home penetration remains comparatively limited in several countries, providing considerable room for Peritoneal Dialysis adoption as governments and providers promote treatment decentralization. Approximately 15% of U.S. dialysis patients currently receive dialysis at home, with Peritoneal Dialysis representing a significant proportion of this population. Modern automated systems increasingly incorporate touchscreen operation, voice guidance, compact equipment, automatic data collection, remote prescription monitoring, and digital clinical dashboards. These features reduce manual recordkeeping while improving clinician visibility into treatment completion. Growing patient preference for independence and less frequent travel to clinical facilities is expected to support gradual market-share expansion through 2035, although infection prevention, patient training, catheter management, and suitability assessments remain important requirements for broader utilization.

By Applications

In-center Dialysis: In-center Dialysis represents approximately 85% of current dialysis treatment activity and remains the dominant application because it provides direct access to nephrologists, trained nurses, technical support, emergency intervention, water-treatment infrastructure, and standardized infection-control procedures. Conventional patients generally receive around 3 treatments per week, with individual sessions commonly lasting about 4 hours, creating continuous demand for clinical capacity. Fresenius Medical Care alone operated 2,622 dialysis clinics in the United States at the end of 2025 and treated approximately 205,483 patients in those facilities. The company delivered approximately 31.07 million U.S. treatments during 2025, demonstrating the scale of recurring facility-based therapy. In-center care remains particularly important for older patients, patients with multiple chronic conditions, individuals with unstable cardiovascular status, and those unable to manage equipment independently at home. New high-volume hemodiafiltration technologies are also initially being deployed through specialized dialysis clinics, reinforcing the role of treatment centers as primary locations for introducing advanced renal replacement therapies.

Home Dialysis: Home Dialysis accounts for approximately 15% of the current U.S. dialysis population and is expected to increase its share throughout the forecast period as patients seek greater scheduling flexibility and healthcare systems pursue decentralized treatment models. More than 15,300 U.S. patients were using NxStage home hemodialysis systems during 2025, approximately 6% higher than the previous year. Home treatment can reduce repeated travel requirements associated with the approximately 3 weekly visits generally required for conventional In-center Dialysis. Digital platforms introduced in 2026 are strengthening adoption by connecting Peritoneal Dialysis and home Hemodialysis treatment information within unified clinical environments. Automated data transfer allows clinicians to review treatment activity remotely, while graphical interfaces and patient guidance simplify equipment operation. Home Dialysis also creates opportunities to increase overall treatment capacity without constructing an equivalent number of physical dialysis stations. Adoption nevertheless depends on patient eligibility, adequate training, suitable living environments, reliable supply delivery, technical assistance, and effective emergency-management procedures.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America holds approximately 38% of the dialysis market and remains the leading regional market because of its large kidney-failure population, mature reimbursement framework, extensive treatment infrastructure, and rapid commercialization of advanced dialysis technologies. The United States has more than 7,500 dialysis facilities and more than 550,000 patients receiving dialysis, making it one of the world's most intensive renal replacement therapy markets. Fresenius Medical Care operated 2,622 U.S. dialysis clinics at the end of 2025 and treated approximately 205,483 patients in its facilities during that year. More than 31 million treatments were delivered through its U.S. network during 2025. These figures demonstrate the substantial recurring treatment requirement created by the country's chronic kidney disease burden and established dependence on facility-based Hemodialysis.

Technology adoption is further strengthening North America's position. During 2025, U.S. regulatory clearance supported deployment of the 5008X hemodiafiltration-capable platform, with broader commercialization progressing through 2026. Home Dialysis is also expanding, with approximately 15% of U.S. dialysis patients currently receiving treatment outside conventional facilities. More than 15,300 patients used NxStage home Hemodialysis systems during 2025, increasing approximately 6% year over year. Digital home-care platforms launched during 2026 now combine remote monitoring for Peritoneal Dialysis and home Hemodialysis within integrated environments. Canada is also promoting home treatment and connected care, supporting regional adoption of automated systems and remote management technologies. North America's advanced reimbursement environment, established dialysis provider networks, high equipment replacement requirements, and early adoption of high-volume hemodiafiltration are expected to preserve its leadership throughout the forecast period.

Europe

Europe accounts for approximately 27% of the dialysis market and maintains a strong position through universal healthcare systems, mature nephrology infrastructure, widespread use of advanced Hemodialysis technologies, and comparatively established adoption of high-volume hemodiafiltration. European treatment centers have used high-volume hemodiafiltration for more than 10 years, giving the region substantial clinical experience with therapies that combine diffusion and convection to improve removal of middle molecules. Germany, France, Italy, Spain, and the United Kingdom represent important treatment markets because of aging populations and persistent prevalence of diabetes, hypertension, and chronic kidney disease. Europe also maintains a substantial manufacturing base for dialysis equipment, dialyzers, bloodlines, water-management systems, and treatment software, supported by several major companies included in the competitive landscape.

European dialysis providers are increasingly emphasizing personalized care, treatment quality, sustainability, digital integration, and home-based renal replacement therapy. Updated versions of advanced hemodialysis systems were introduced during 2025 in alignment with newer European medical-device requirements, supporting replacement demand across dialysis centers. Home Dialysis is gaining attention as healthcare systems seek to reduce repeated travel requirements and improve patient autonomy, particularly for clinically suitable patients. Connected Peritoneal Dialysis platforms allow clinicians to monitor completed treatment sessions and modify care plans remotely, reducing dependence on manual treatment records. Europe also benefits from extensive clinical evidence supporting high-volume hemodiafiltration, encouraging treatment providers to incorporate higher-efficiency therapy into routine practice. These conditions are expected to sustain moderate but stable growth through 2035 even as established dialysis penetration limits the rate of new facility expansion compared with emerging regions.

Asia-Pacific

Asia-Pacific represents approximately 25% of the dialysis market and is expected to record the fastest regional expansion through 2035 as chronic kidney disease prevalence rises alongside diabetes, hypertension, urbanization, and population aging. More than 2 million people across Asia-Pacific are estimated to receive dialysis, although treatment availability varies considerably between high-income and emerging economies. Japan maintains one of the world's most established Hemodialysis populations, while China continues expanding dialysis centers and domestic manufacturing capacity. India and Southeast Asian economies are also increasing access through public healthcare programs, private hospital networks, specialty dialysis chains, and lower-cost treatment models. The large gap between diagnosed kidney failure and available treatment capacity creates substantial long-term demand for new dialysis stations, consumables, trained personnel, and home-treatment solutions.

Regional growth is also being influenced by stronger domestic manufacturing and increasing adoption of advanced equipment. Japan-based suppliers such as Nipro Corporation, Nikkiso Co. Ltd., JMS Co., Ltd., Terumo, and Asahi Kasei Corporation provide significant dialysis technology capabilities across machines, dialyzers, bloodlines, and associated products. China continues to expand treatment capacity through both local and international equipment suppliers, while India's dialysis infrastructure is growing beyond major metropolitan centers. Peritoneal Dialysis offers particular potential in geographically dispersed populations because home treatment can reduce repeated travel to urban dialysis facilities. Asia-Pacific's approximately 25% market participation is therefore expected to rise as healthcare coverage improves and governments increase investment in renal care. The combination of large untreated patient populations, infrastructure expansion, rising insurance penetration, and lower-cost equipment manufacturing positions the region for the fastest long-term growth.

Middle East & Africa

Middle East & Africa accounts for approximately 10% of the dialysis market and presents a combination of advanced treatment systems in wealthier Gulf economies and significant access limitations across lower-income countries. Saudi Arabia, the United Arab Emirates, Qatar, and other Gulf markets are investing in modern renal treatment centers, digital healthcare systems, and advanced Hemodialysis equipment as diabetes and hypertension increase chronic kidney disease risk. Several Middle Eastern countries have comparatively high diabetes prevalence, creating sustained pressure on nephrology services. High-volume hemodiafiltration has been used across parts of the broader EMEA region for more than a decade, supporting adoption of higher-efficiency treatment approaches in major tertiary care facilities.

Africa presents substantial unmet need because treatment access remains concentrated in urban centers while many patients face limitations related to affordability, travel distance, infrastructure, specialist availability, and reliable water and electricity supplies. Expansion of compact Hemodialysis equipment and Peritoneal Dialysis could improve treatment accessibility in underserved areas, particularly where constructing large dialysis centers is difficult. Home-based therapy nevertheless requires dependable logistics, patient education, clinical monitoring, and consistent access to consumables. Governments and private healthcare operators are increasingly using public-private partnerships to expand renal care infrastructure, while international providers continue establishing specialized centers in selected markets. With approximately 10% of the global market currently represented by the region, substantial long-term potential remains as diagnosis rates, insurance coverage, treatment capacity, and chronic disease management improve.

List of Top Dialysis Companies

• JMS Co., Ltd.
• Fresenius Medical Care AG & Co. KGaA
• Terumo
• Asahi Kasei Corporation
• Baxter International, Inc.
• DaVita Inc.
• Nikkiso Co. Ltd.
• NxStage Medical, Inc.
• Medicators, Inc
• Nipro Corporation
• B. Braun Avitum AG
• Diaverum Deutschland GmbH

Top 2 Companies Market Share

Fresenius Medical Care AG & Co. KGaA: The company maintains one of the strongest competitive positions in the global dialysis industry, holding approximately 35% of the worldwide dialysis-products market during 2025 and more than 40% of the Hemodialysis-products segment. Its scale is particularly visible in equipment manufacturing, as the company produced approximately 56,000 of the estimated 110,000 Hemodialysis machines installed globally during 2025, equivalent to around 50% of annual machine installations. Fresenius Medical Care also manufactured approximately 171 million of the roughly 450 million dialyzers used globally during 2025, corresponding to about 38% of worldwide dialyzer volume. Its competitive strength extends beyond manufacturing through an extensive care-delivery network, integrated digital platforms, home dialysis systems, and high-volume hemodiafiltration technology.

Baxter International, Inc.: Baxter maintains an estimated 20% share across relevant global dialysis equipment and therapy segments, with particular competitive strength in Peritoneal Dialysis and connected home-treatment systems. The company's automated Peritoneal Dialysis portfolio combines compact cyclers with remote patient-management technology that automatically transfers completed treatment information to healthcare teams. This positioning is increasingly important as approximately 15% of U.S. dialysis patients currently receive treatment at home and healthcare providers seek to increase patient independence. Baxter's installed Peritoneal Dialysis base spans multiple international markets, giving the company a substantial recurring presence in solutions, disposables, and connected care. Its focus on automated therapy, remote clinical visibility, user-friendly interfaces, and home-centered treatment supports continued competition as decentralized kidney care expands through 2035.

Investment Analysis

Investment activity in the dialysis market is increasingly directed toward home-treatment platforms, digital connectivity, higher-efficiency Hemodialysis systems, manufacturing capacity, and value-based kidney care. The installation of approximately 110,000 Hemodialysis machines worldwide during 2025, up from roughly 100,000 in 2024, demonstrates continued capital requirements for equipment expansion and replacement. Approximately 450 million dialyzers were consumed globally during 2025, indicating a large recurring consumables requirement alongside capital equipment investment. Investors and manufacturers are therefore targeting technologies that can improve utilization, automate clinical workflows, extend equipment life, and support treatment outside conventional centers. High-volume hemodiafiltration is gaining particular attention after regulatory milestones in the United States, while connected Home Dialysis solutions are benefiting from approximately 6% annual growth in the number of U.S. patients using certain home Hemodialysis platforms during 2025.

Emerging economies provide another major investment pathway because Asia-Pacific already represents approximately 25% of market activity yet retains significant unmet dialysis demand. Expansion opportunities include construction of outpatient centers, manufacturing of dialyzers and bloodlines, local assembly of dialysis machines, development of water-treatment infrastructure, and distribution networks for Peritoneal Dialysis supplies. Private providers can also expand through hub-and-spoke models that connect urban nephrology centers with smaller regional treatment locations. Digital investment is increasingly important because more than 150 Hemodialysis sessions can be required annually for a conventional long-term patient, generating substantial clinical and operational data. Platforms capable of connecting equipment, patient records, treatment prescriptions, remote monitoring, and predictive analytics can therefore improve clinical scalability. Investment strategies through 2035 are expected to favor integrated businesses that combine equipment, consumables, software, logistics, and care-delivery capabilities rather than relying on isolated product categories.

New Product Development

New product development is concentrating on connected Home Dialysis systems, advanced hemodiafiltration platforms, digital treatment analytics, improved dialyzer membranes, simplified patient interfaces, and stronger cybersecurity. Fresenius Medical Care's 5008X platform received U.S. regulatory clearance during 2025 and supports hemodiafiltration, allowing treatment to combine diffusion with high-volume convection. Initial U.S. treatments began during 2025, followed by broader expansion activity during 2026. Dialysis-fluid filtration technology is also evolving to support ultrapure dialysis fluid and sterile substitution fluid for hemodiafiltration. These innovations are particularly important as approximately 450 million dialyzers and 110,000 Hemodialysis machines were required globally during 2025. Equipment manufacturers are therefore seeking improvements in membrane performance, fluid management, automation, monitoring accuracy, machine reliability, touchscreen usability, and treatment personalization while ensuring that newer systems can integrate with hospital and outpatient information environments.

Home-focused development is moving toward unified ecosystems rather than isolated machines. In June 2026, Fresenius Medical Care introduced a worldwide digital platform capable of supporting both Peritoneal Dialysis and home Hemodialysis workflows within a single connected environment. This approach reflects the growing importance of remote patient management as approximately 15% of U.S. dialysis patients now receive treatment at home. Automated Peritoneal Dialysis equipment increasingly incorporates graphical or voice guidance, touchscreen controls, automatic treatment-data collection, and remote clinical access, while newer home Hemodialysis systems emphasize compact design and simplified workflows. Product developers are also increasing attention to cybersecurity because connected dialysis devices continuously exchange treatment information with remote systems. Future product differentiation is consequently expected to depend on a combination of clinical efficiency, digital interoperability, patient usability, predictive analytics, portability, and dependable remote-support capabilities.

Five Recent Developments

• July 2026: Fresenius Medical Care announced the BEACON-US initiative to generate real-world evidence for high-volume hemodiafiltration across U.S. clinical practice, expanding evaluation of a therapy already supported by treatment experience across more than 90 countries.
• June 2026: Fresenius Medical Care launched its kinexus digital platform worldwide, integrating remote therapy monitoring and operational workflows for Peritoneal Dialysis and home Hemodialysis into 1 unified environment designed to strengthen connected home renal care.
• June 2025: Fresenius Medical Care advanced the latest 5008X CAREsystem following U.S. regulatory clearance, supporting high-volume hemodiafiltration and preparing broader commercialization for 2026 after initial treatment implementation at selected U.S. dialysis facilities.
• May 2025: The 5008X Hemodialysis System received a U.S. regulatory decision supporting its updated configuration, providing an important milestone for introduction of hemodiafiltration technology in a market where conventional Hemodialysis remains the dominant treatment modality.
• 2024: Fresenius Medical Care secured an earlier U.S. regulatory clearance for a version of its CAREsystem, creating the foundation for subsequent 2025 upgrades and the broader introduction of high-volume hemodiafiltration technology across U.S. dialysis treatment settings.

Report Coverage

This Dialysis Market report evaluates industry conditions across the 2025-2035 period, using 2026 as the principal near-term market reference point and assessing a forecast CAGR of 6.08%. The coverage examines Hemodialysis and Peritoneal Dialysis across In-center Dialysis and Home Dialysis applications while considering treatment infrastructure, patient adoption, equipment installation, clinical trends, technology development, digital integration, regional expansion, investment activity, and competitive positioning. Hemodialysis currently represents approximately 88% of treatment activity, while Peritoneal Dialysis accounts for about 12%. Application analysis identifies In-center Dialysis at approximately 85% and Home Dialysis at approximately 15% of current U.S. treatment participation. Regional assessment covers North America at approximately 38%, Europe at 27%, Asia-Pacific at 25%, and Middle East & Africa at 10%, providing a complete 100% geographic distribution for comparative analysis.

The competitive assessment covers JMS Co., Ltd., Fresenius Medical Care AG & Co. KGaA, Terumo, Asahi Kasei Corporation, Baxter International, Inc., DaVita Inc., Nikkiso Co. Ltd., NxStage Medical, Inc., Medicators, Inc, Nipro Corporation, B. Braun Avitum AG, and Diaverum Deutschland GmbH. The report evaluates market concentration through equipment production, treatment networks, home therapy capabilities, digital platforms, and product-development activity. Approximately 450 million Hemodialysis dialyzers were used globally during 2025, while around 110,000 Hemodialysis machines were installed, illustrating the scale of recurring product demand and equipment replacement. The coverage also assesses emerging high-volume hemodiafiltration, remote patient management, automated Peritoneal Dialysis, connected Home Dialysis, and treatment analytics. Particular attention is given to Asia-Pacific's approximately 25% share and its faster infrastructure expansion, alongside North America's approximately 38% position and continued leadership in advanced renal-care technology adoption.